News
HALO
56.23
+0.46%
0.26
Artisan Global Equity Fund Q2 2024 Commentary
Artisan Global Equity Fund Q2 2024 Commentary. With inflation slowing in many countries, equity markets saw modest returns in Q2. Stocks in emerging markets and North America performed particularly well. The portfolio came up short against its benchmark, the MSCI AC World Index.
Seeking Alpha · 20h ago
Maintaining a Hold: Assessing Halozyme’s ENHANZE Amidst Emerging Competitive Threats and Patent Dynamics
TipRanks · 1d ago
Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy
NASDAQ · 3d ago
Halozyme Therapeutics Is Maintained at Neutral by Goldman Sachs
Dow Jones · 4d ago
Halozyme Therapeutics Price Target Raised to $49.00/Share From $44.00 by Goldman Sachs
Dow Jones · 4d ago
Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $49
Benzinga · 4d ago
Healthcare 2024 Second Half Outlook
Seeking Alpha · 4d ago
Weekly Report: what happened at HALO last week (0715-0719)?
Weekly Report · 4d ago
Laughing Water Capital Q2 2024 Letter
Seeking Alpha · 07/19 11:32
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
NASDAQ · 07/17 15:27
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a 22x price-to-earnings ratio. The company has a strong earnings growth rate compared to the rest of the U.S. Industry. Its P/E ratio is higher than the average for companies in the United States. It is expected to grow earnings by 35% over the next three years. The stock has been trading at a high level due to its strong future growth.
Simply Wall St · 07/17 11:44
Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares
NASDAQ · 07/16 17:20
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Halozyme Therapeutics has been analyzed by 13 analysts in the last three months. The company is a biotechnology company focused on developing and commercializing novel oncology therapies. The 12-month price targets assessed by analysts reveal an average target of $57.69.
Benzinga · 07/16 12:00
Halozyme Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.
Dow Jones · 07/16 11:56
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Benzinga · 07/16 11:46
Optimistic Outlook for Halozyme: Buy Rating Backed by Regulatory Success and Robust Technology
TipRanks · 07/16 10:32
Weekly Report: what happened at HALO last week (0708-0712)?
Weekly Report · 07/15 09:10
Top Medical Stocks to Buy for Growth & Performance
NASDAQ · 07/10 21:00
How to Find Strong Buy Medical Stocks Using the Zacks Rank
NASDAQ · 07/10 13:00
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
NASDAQ · 07/10 12:30
More
Webull provides a variety of real-time HALO stock news. You can receive the latest news about Halozyme Thrp through multiple platforms. This information may help you make smarter investment decisions.
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.